– Industry veteran strengthens Sensydia’s leadership team as company advances toward FDA submission –

LOS ANGELES: Sensydia, a medical technology company advancing non-invasive cardiac assessment, today announced the appointment of Rusty Page as President and Chief Operating Officer. Page joins Sensydia from publicly traded Neuronetics, Inc., where he served as SVP, Chief Information & Operations Officer. He brings more than two decades of senior leadership experience in the medical device and diagnostics industry.

At Sensydia, Mr. Page will have broad responsibility for operations, quality, IT, and business infrastructure as the company prepares for regulatory submission and commercial launch of its non-invasive Cardiac Performance System (CPS™).

“Rusty’s track record guiding early-stage medical device companies from development through product launch and commercialization makes him an ideal addition to Sensydia’s leadership team,” said Anthony Arnold, CEO of Sensydia. “His operational and strategic expertise will be instrumental as we scale for growth and take CPS to the market.”

At Neuronetics, Mr. Page oversaw operations, quality, field service, information technology, international business development, and acquisitions. Previously, he held multiple executive roles across the industry, including as Vice President of Operations and Quality and General Manager at Bioness, where he was a founding team member and helped lead the company through significant growth, multiple product launches, and the company’s successful acquisition by Bioventus in 2021.

“I’m thrilled to join Sensydia at such a pivotal time in the company’s journey,” said Rusty Page. “The potential of the Cardiac Performance System to transform cardiovascular care is truly exciting, and I look forward to helping scale Sensydia’s operations and to support its path toward commercialization.”

Mr. Page brings a deep and diverse understanding of medical device companies, having led functions across global supply chain, manufacturing, regulatory compliance, and quality systems, including those regulated by FDA and international regulatory bodies.

About Sensydia

Sensydia is developing the Cardiac Performance System (CPS™), a non-invasive platform that provides real-time measurements of critical cardiac function. CPS is designed to deliver rapid, safe, and accurate assessments to improve outcomes for patients with heart failure and pulmonary hypertension. The company received FDA 510(k) clearance for non-invasive measurement of ejection fraction using first-generation hardware in 2018. Learn more at sensydia.com.

Fonte: Business Wire